HMGvsPT-141

Human Menopausal Gonadotropin is a purified urinary extract containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, sourced from the urine of postmenopausal women. After menopause, the loss of ovarian negative feedback (estradiol and inhibin) results in dramatically elevated pituitary gonadotropin secretion — FSH and LH levels rise 10-20 fold, providing a natural source of these hormones for pharmaceutical extraction.

The FSH component binds to FSH receptors (FSHR) on Sertoli cells in males and granulosa cells in females. FSHR is a Gs-coupled GPCR that activates cAMP/PKA signaling, driving the expression of genes essential for gametogenesis. In males, FSH-stimulated Sertoli cells produce androgen-binding protein (which concentrates testosterone locally), inhibin B (which provides negative feedback to the pituitary), and multiple growth factors that support spermatogonial proliferation and differentiation through the stages of spermatogenesis. In females, FSH drives follicular development — stimulating granulosa cell proliferation, estradiol synthesis via aromatase induction, and the growth of ovarian follicles from the pre-antral to the pre-ovulatory stage.

The LH component acts on Leydig cells in males (stimulating testosterone production via the LHCGR/cAMP/StAR steroidogenic pathway) and on theca cells in females (stimulating androgen precursor production that granulosa cells convert to estradiol). In females undergoing fertility treatment, the LH component is also critical for final oocyte maturation and ovulation triggering. The combination of both FSH and LH activity in HMG provides more complete gonadal stimulation than either gonadotropin alone — FSH drives the cellular proliferation and maturation processes while LH provides the steroidogenic and final maturation signals. This dual activity is why HMG is sometimes preferred over purified FSH preparations in certain fertility protocols, particularly in hypogonadotropic patients who lack endogenous LH.

PT-141 (bremelanotide) is a cyclic heptapeptide derived from Melanotan II through targeted structural modification to shift receptor selectivity toward MC4R and away from MC1R. It was developed specifically to capture the sexual arousal effects observed with MT-II while minimizing the unwanted tanning (MC1R-mediated) effects. The result is a peptide that acts primarily on the central nervous system rather than peripheral vasculature.

PT-141 activates melanocortin 4 receptors (MC4R) in key brain regions involved in sexual function, particularly the medial preoptic area, the paraventricular nucleus of the hypothalamus, and descending autonomic pathways. MC4R is a Gs-coupled GPCR that increases intracellular cAMP, activating neural circuits that regulate sexual desire, arousal, and physiological sexual response. This central mechanism is fundamentally different from PDE5 inhibitors (sildenafil, tadalafil), which work peripherally by enhancing nitric oxide-mediated vasodilation in penile and clitoral erectile tissue. PDE5 inhibitors improve the mechanical response to arousal but do not affect desire; PT-141 acts upstream, enhancing the desire and arousal signals that originate in the brain.

In women with hypoactive sexual desire disorder (HSDD), PT-141 activates these hypothalamic sexual arousal circuits to increase desire, sexual arousal, and genital response. The nausea experienced by approximately 40% of users is attributed to MC4R activation in the area postrema (the vomiting center in the brainstem), which lies outside the blood-brain barrier and is therefore accessible to circulating peptides. The transient blood pressure elevation results from sympathetic nervous system activation downstream of hypothalamic MC4R signaling. PT-141 retains some residual MC1R activity, which can produce mild facial flushing, but at therapeutic doses the tanning effect is minimal compared to MT-II.